This article is more than 5 years old. Information may no longer be current.

VIDEO: Women with osteoporosis had reduction in vertebral, nonvertebral fractures with abaloparatide, alendronate

Add topic to email alerts

Receive an email when new articles are posted on

Please provide your email address to receive an email when new articles are posted on .

Subscribe

Added to email alerts

You've successfully added to your alerts. You will receive an email when new content is published.

Click Here to Manage Email Alerts

You've successfully added to your alerts. You will receive an email when new content is published.

Click Here to Manage Email Alerts

Back to Healio

We were unable to process your request. Please try again later. If you continue to have this issue please contact customerservice@slackinc.com.

Back to Healio

SAN DIEGO — At the American College of Rheumatology Annual Meeting, Robin K. Dore, MD, spoke about results of the ACTIVExtend trial of postmenopausal women with osteoporosis. She said results showed that women who received abaloparatide for 18 months followed by 24 months of alendronate had a sustained decrease of vertebral and nonvertebral fractures compared to women who received placebo followed by alendronate.